Special Issue: “Molecules against Alzheimer”

This Special Issue, entitled “Molecules against Alzheimer”, gathers a number of original articles, short communications, and review articles on recent research efforts toward the development of novel drug candidates, diagnostic agents and therapeutic approaches for Alzheimer’s disease (AD), the most...

Full description

Bibliographic Details
Main Authors: Michael Decker, Diego Muñoz-Torrero
Format: Article
Language:English
Published: MDPI AG 2016-12-01
Series:Molecules
Subjects:
Online Access:http://www.mdpi.com/1420-3049/21/12/1736
id doaj-7438f1322ca543738f031434119f0806
record_format Article
spelling doaj-7438f1322ca543738f031434119f08062020-11-25T00:22:44ZengMDPI AGMolecules1420-30492016-12-012112173610.3390/molecules21121736molecules21121736Special Issue: “Molecules against Alzheimer”Michael Decker0Diego Muñoz-Torrero1Pharmazeutische und Medizinische Chemie, Institut für Pharmazie und Lebensmittelchemie, Julius-Maximilians-Universität Würzburg, Am Hubland, 97074 Würzburg, GermanyLaboratory of Pharmaceutical Chemistry, Faculty of Pharmacy and Food Sciences, and Institute of Biomedicine (IBUB), University of Barcelona, Av. Joan XXIII, 27-31, E-08028 Barcelona, SpainThis Special Issue, entitled “Molecules against Alzheimer”, gathers a number of original articles, short communications, and review articles on recent research efforts toward the development of novel drug candidates, diagnostic agents and therapeutic approaches for Alzheimer’s disease (AD), the most prevalent neurodegenerative disorder and a leading cause of death worldwide. This Special Issue contains many interesting examples describing the design, synthesis, and pharmacological profiling of novel compounds that hit one or several key biological targets, such as cholinesterases, β-amyloid formation or aggregation, monoamine oxidase B, oxidative stress, biometal dyshomeostasis, mitochondrial dysfunction, serotonin and/or melatonin systems, the Wnt/β-catenin pathway, sigma receptors, nicotinamide phosphoribosyltransferase, or nuclear erythroid 2-related factor. The development of novel AD diagnostic agents based on tau protein imaging and the use of lithium or intranasal insulin for the prevention or the symptomatic treatment of AD is also covered in some articles of the Special Issue.http://www.mdpi.com/1420-3049/21/12/1736Alzheimer’s diseasedrug discoveryrational designhybrid moleculesmulti-target-directed moleculespolypharmacologyimaging agentsneuroprotectantsneurogenic molecules
collection DOAJ
language English
format Article
sources DOAJ
author Michael Decker
Diego Muñoz-Torrero
spellingShingle Michael Decker
Diego Muñoz-Torrero
Special Issue: “Molecules against Alzheimer”
Molecules
Alzheimer’s disease
drug discovery
rational design
hybrid molecules
multi-target-directed molecules
polypharmacology
imaging agents
neuroprotectants
neurogenic molecules
author_facet Michael Decker
Diego Muñoz-Torrero
author_sort Michael Decker
title Special Issue: “Molecules against Alzheimer”
title_short Special Issue: “Molecules against Alzheimer”
title_full Special Issue: “Molecules against Alzheimer”
title_fullStr Special Issue: “Molecules against Alzheimer”
title_full_unstemmed Special Issue: “Molecules against Alzheimer”
title_sort special issue: “molecules against alzheimer”
publisher MDPI AG
series Molecules
issn 1420-3049
publishDate 2016-12-01
description This Special Issue, entitled “Molecules against Alzheimer”, gathers a number of original articles, short communications, and review articles on recent research efforts toward the development of novel drug candidates, diagnostic agents and therapeutic approaches for Alzheimer’s disease (AD), the most prevalent neurodegenerative disorder and a leading cause of death worldwide. This Special Issue contains many interesting examples describing the design, synthesis, and pharmacological profiling of novel compounds that hit one or several key biological targets, such as cholinesterases, β-amyloid formation or aggregation, monoamine oxidase B, oxidative stress, biometal dyshomeostasis, mitochondrial dysfunction, serotonin and/or melatonin systems, the Wnt/β-catenin pathway, sigma receptors, nicotinamide phosphoribosyltransferase, or nuclear erythroid 2-related factor. The development of novel AD diagnostic agents based on tau protein imaging and the use of lithium or intranasal insulin for the prevention or the symptomatic treatment of AD is also covered in some articles of the Special Issue.
topic Alzheimer’s disease
drug discovery
rational design
hybrid molecules
multi-target-directed molecules
polypharmacology
imaging agents
neuroprotectants
neurogenic molecules
url http://www.mdpi.com/1420-3049/21/12/1736
work_keys_str_mv AT michaeldecker specialissuemoleculesagainstalzheimer
AT diegomunoztorrero specialissuemoleculesagainstalzheimer
_version_ 1725358511091613696